Octagon Capital Advisors LP Taysha Gene Therapies, Inc. Transaction History
Octagon Capital Advisors LP
- $307 Million
- Q3 2025
A detailed history of Octagon Capital Advisors LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 9,067,500 shares of TSHA stock, worth $38.2 Million. This represents 9.31% of its overall portfolio holdings.
Number of Shares
9,067,500
Previous 12,592,500
27.99%
Holding current value
$38.2 Million
Previous $29.1 Million
1.81%
% of portfolio
9.31%
Previous 11.04%
Shares
9 transactions
Others Institutions Holding TSHA
# of Institutions
160Shares Held
247MCall Options Held
463KPut Options Held
246K-
Rtw Investments, LP New York, NY24.4MShares$103 Million1.03% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$99.2 Million1.27% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$91.4 Million0.93% of portfolio
-
Morgan Stanley New York, NY19.3MShares$81.3 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY13.4MShares$56.3 Million0.01% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $204M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...